-
Something wrong with this record ?
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
H. Ludwig, MA. Dimopoulos, P. Moreau, WJ. Chng, H. Goldschmidt, R. Hájek, T. Facon, L. Pour, R. Niesvizky, A. Oriol, L. Rosiñol, A. Suvorov, G. Gaidano, T. Pika, K. Weisel, V. Goranova-Marinova, A. Palumbo, HH. Gillenwater, N. Mohamed, S....
Language English Country United States
Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial
- MeSH
- Bortezomib administration & dosage MeSH
- Dexamethasone administration & dosage MeSH
- Humans MeSH
- Neoplasm Recurrence, Local drug therapy pathology MeSH
- Survival Rate MeSH
- Multiple Myeloma drug therapy pathology MeSH
- Follow-Up Studies MeSH
- Oligopeptides administration & dosage MeSH
- Prognosis MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Aged MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
b School of Medicine National and Kapodistrian University of Athens Athens Greece
c University of Nantes Nantes France
h Heidelberg Medical University Heidelberg Germany
Hospital Clínic de Barcelona Barcelona Spain
i University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic
j CHRU Lille Hôpital Claude Huriez Lille France
k University Hospital Brno Brno Czech Republic
l Weill Cornell Medical College New York Presbyterian Hospital New York NY USA
m Institut Català d'Oncologia Institut Josep Carreras Hospital Germans Trias i Pujol Barcelona Spain
o 1st Republican Clinical Hospital of Udmurtia Izhevsk Russia
p Department of Translational Medicine University of Eastern Piedmont Novara Italy
q University Hospital Olomouc Olomouc Czech Republic
r Universitatsklinikum Tubingen Tubingen Germany
t University of Torino Torino Italy
u Onyx Pharmaceuticals Inc an Amgen subsidiary South San Francisco CA USA
v Royal Prince Alfred Hospital Camperdown New South Wales Australia
Wilhelminen Cancer Research Institute Wilhelminenspital Vienna Austria
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19013172
- 003
- CZ-PrNML
- 005
- 20190412121532.0
- 007
- ta
- 008
- 190405s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/10428194.2017.1298755 $2 doi
- 035 __
- $a (PubMed)28306371
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ludwig, Heinz $u a Wilhelminen Cancer Research Institute, Wilhelminenspital , Vienna , Austria.
- 245 10
- $a Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup / $c H. Ludwig, MA. Dimopoulos, P. Moreau, WJ. Chng, H. Goldschmidt, R. Hájek, T. Facon, L. Pour, R. Niesvizky, A. Oriol, L. Rosiñol, A. Suvorov, G. Gaidano, T. Pika, K. Weisel, V. Goranova-Marinova, A. Palumbo, HH. Gillenwater, N. Mohamed, S. Aggarwal, S. Feng, D. Joshua,
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a bortezomib $x aplikace a dávkování $7 D000069286
- 650 _2
- $a dexamethason $x aplikace a dávkování $7 D003907
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mnohočetný myelom $x farmakoterapie $x patologie $7 D009101
- 650 _2
- $a lokální recidiva nádoru $x farmakoterapie $x patologie $7 D009364
- 650 _2
- $a oligopeptidy $x aplikace a dávkování $7 D009842
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Dimopoulos, Meletios A $u b School of Medicine, National and Kapodistrian University of Athens , Athens , Greece.
- 700 1_
- $a Moreau, Philippe $u c University of Nantes , Nantes , France.
- 700 1_
- $a Chng, Wee-Joo $u d National University Cancer Institute, Singapore. e National University Health System, Singapore. f Cancer Science Institute, Singapore. g National University of Singapore , Singapore.
- 700 1_
- $a Goldschmidt, Hartmut $u h Heidelberg Medical University , Heidelberg , Germany.
- 700 1_
- $a Hájek, Roman $u i University Hospital Ostrava and Faculty of Medicine, University of Ostrava , Ostrava , Czech Republic.
- 700 1_
- $a Facon, Thierry $u j CHRU Lille Hôpital Claude Huriez , Lille , France.
- 700 1_
- $a Pour, Ludek $u k University Hospital Brno , Brno , Czech Republic.
- 700 1_
- $a Niesvizky, Ruben $u l Weill Cornell Medical College/New York Presbyterian Hospital , New York , NY , USA.
- 700 1_
- $a Oriol, Albert $u m Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol , Barcelona , Spain.
- 700 1_
- $a Rosiñol, Laura $u n Hospital Clínic de Barcelona , Barcelona , Spain.
- 700 1_
- $a Suvorov, Aleksandr $u o First Republican Clinical Hospital of Udmurtia , Izhevsk , Russia.
- 700 1_
- $a Gaidano, Gianluca $u p Department of Translational Medicine , University of Eastern Piedmont , Novara , Italy.
- 700 1_
- $a Pika, Tomas $u q University Hospital Olomouc , Olomouc , Czech Republic.
- 700 1_
- $a Weisel, Katja $u r Universitatsklinikum Tubingen , Tubingen , Germany.
- 700 1_
- $a Goranova-Marinova, Vesselina $u s University Multiprofile Hospital for Active Treatment "Sv. Georgi" and Medical University , Plovdiv , Bulgaria.
- 700 1_
- $a Palumbo, Antonio $u t University of Torino , Torino , Italy.
- 700 1_
- $a Gillenwater, Heidi H $u u Onyx Pharmaceuticals, Inc, an Amgen subsidiary , South San Francisco , CA , USA.
- 700 1_
- $a Mohamed, Nehal $u u Onyx Pharmaceuticals, Inc, an Amgen subsidiary , South San Francisco , CA , USA.
- 700 1_
- $a Aggarwal, Sanjay $u u Onyx Pharmaceuticals, Inc, an Amgen subsidiary , South San Francisco , CA , USA.
- 700 1_
- $a Feng, Shibao $u u Onyx Pharmaceuticals, Inc, an Amgen subsidiary , South San Francisco , CA , USA.
- 700 1_
- $a Joshua, Douglas $u v Royal Prince Alfred Hospital , Camperdown , New South Wales , Australia.
- 773 0_
- $w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 58, č. 10 (2017), s. 2501-2504
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28306371 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190412121551 $b ABA008
- 999 __
- $a ok $b bmc $g 1392482 $s 1051477
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 58 $c 10 $d 2501-2504 $e 20170317 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- LZP __
- $a Pubmed-20190405